Compare
AtriCure, Inc. vs Glaukos Corp vs Bioventus Inc. vs UFP Technologies Inc
| Latest fiscal year | AtriCure, Inc. ATRC | Glaukos Corp GKOS | Bioventus Inc. BVS | UFP Technologies Inc UFPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $534.53M | $507.44M | $568.09M | $602.80M |
| Revenue growth (YoY) | +14.9% | +32.3% | -0.9% | +19.5% |
| Gross margin | 75.0% | 55.7% | 68.3% | 28.3% |
| Operating margin | -1.8% | -39.3% | 9.5% | 15.3% |
| Net margin | -2.1% | -37.0% | 4.0% | 11.3% |
| Net income | -$11.45M | -$187.69M | $22.73M | $68.31M |
| EPS (Diluted) | -$0.24 | -$3.28 | $0.33 | $8.75 |
| Operating cash flow | $57.33M | -$14.79M | $74.67M | $91.91M |
| Free cash flow | $48.28M | -$22.45M | $72.11M | n/a |
| Cash & equivalents | $167.43M | $90.81M | $51.24M | $20.30M |
| Total assets | $654.18M | $893.49M | $683.56M | $655.08M |
| Total liabilities | $162.24M | $237.33M | $455.11M | $231.20M |
| Shareholders' equity | $491.94M | $656.15M | $184.10M | $423.88M |
| Return on year-end equity | -2.3% | -28.6% | 12.3% | 16.1% |
| Shares outstanding | 49.79M | 57.51M | n/a | 7.71M |
Revenue, most recent five fiscal years
| Fiscal year | AtriCure, Inc. | Glaukos Corp | Bioventus Inc. | UFP Technologies Inc |
|---|---|---|---|---|
| Latest | $534.53M Ended 2025-12-31 | $507.44M Ended 2025-12-31 | $568.09M Ended 2025-12-31 | $602.80M Ended 2025-12-31 |
| 1 year earlier | $465.31M Ended 2024-12-31 | $383.48M Ended 2024-12-31 | $573.28M Ended 2024-12-31 | $504.42M Ended 2024-12-31 |
| 2 years earlier | $399.25M Ended 2023-12-31 | $314.71M Ended 2023-12-31 | $512.35M Ended 2023-12-31 | $400.07M Ended 2023-12-31 |
| 3 years earlier | $330.38M Ended 2022-12-31 | $282.86M Ended 2022-12-31 | $512.12M Ended 2022-12-31 | $353.79M Ended 2022-12-31 |
| 4 years earlier | $274.33M Ended 2021-12-31 | $294.01M Ended 2021-12-31 | $430.90M Ended 2021-12-31 | $206.32M Ended 2021-12-31 |